Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29165183 | 0.86 | ALDH1A1 (0.59) | EGFRERBB2ALDH1A1LMNAALB | |
| SCHEMBL8545310 | 0.85 | EGFR (0.60) | EGFRERBB2ALDH1A1LMNAALB | |
| SCHEMBL28405273 | 0.85 | EGFR (0.60) | EGFRERBB2ALDH1A1LMNAALB | |
| SCHEMBL6859141 | 0.84 | ALDH1A1 (0.59) | EGFRERBB2ALDH1A1CA1CA2 | |
| SCHEMBL2635660 | 0.84 | EGFR (0.63) | EGFRERBB2ALDH1A1LMNAALB | |
| SCHEMBL15650208 | 0.84 | ALDH1A1 (0.69) | ALDH1A1LMNATSHRTDP1CA1 | |
| SCHEMBL19630969 | 0.84 | EGFR (0.68) | EGFRERBB2ALDH1A1LMNATSHR | |
| SCHEMBL5931139 | 0.84 | ALDH1A1 (0.71) | EGFRERBB2ALDH1A1LMNAALB | |
| SCHEMBL13537908 | 0.84 | CA1 (0.68) | EGFRERBB2ALDH1A1LMNAALB | |
| SCHEMBL386093 | 0.83 | KDM4E (0.57) | EGFRERBB2CA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117623992-A | Lewis acid-promoted N-acyl sulfonamide direct transfer acylation method | 荆楚理工学院 | 2024-03-01 | — | — | CN | disclosed |
| CN-117603101-A | Lewis acid-promoted non-hydrolytic deacylation method for N-acyl secondary sulfonamide | 荆楚理工学院 | 2024-02-27 | — | — | CN | disclosed |
| CN-108883650-A | Method and apparatus for processing lithographic printing plate | 爱克发有限公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-108778769-A | The method and apparatus for processing lithographic printing plate | 爱克发有限公司 | 2018-11-09 | — | — | CN | disclosed |
| US-9056862-B2 | Thioxothiazolidine derivative having Ras function inhibitory effect | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2015-06-16 | — | — | US | disclosed |
| US-9056862-B2 | Thioxothiazolidine derivative having Ras function inhibitory effect | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2015-06-16 | — | — | US | disclosed |
| US-20140194412-A1 | THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT | KNC LABORATORIES CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20140194412-A1 | THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT | KNC LABORATORIES CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20100222410-A1 | Nuclease compositions and methods | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2009141657-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | KARUS THERAPEUTICS LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222410-A1 | Nuclease compositions and methods | YBX3, RNASEL, RNASEH1 | EGFR 3421/4885ERBB2 3717/4885ALDH1A1 3884/4885 |
| US-20140194412-A1 | THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT | KRAS, NRAS, RASSF5 | EGFR 616/4885ERBB2 710/4885ALDH1A1 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.